Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPALAN vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin at the presynaptic terminal.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
Major depressive disorder,Generalized anxiety disorder,Obsessive-compulsive disorder,Panic disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
Hypertension
100 mg orally twice daily
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Terminal elimination half-life is 12-14 hours in adults with normal renal function; prolonged to 24-36 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 60 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Hepatic via CYP2D6 and CYP3A4; active metabolite N-desmethylserpalan.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Primarily renal elimination (60-70% unchanged drug), with 20-30% biliary/fecal excretion as metabolites; less than 10% excreted unchanged in feces.
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Approximately 85-90% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein.
Approximately 70-80% bound to plasma proteins, primarily albumin.
1.2-1.8 L/kg, indicating extensive tissue distribution (e.g., liver, kidneys, and lungs); higher Vd in obese patients.
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Oral: 75-85% due to first-pass metabolism; IM: 90-98%; rectal: 50-70%.
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
GFR ≥ 60 m L/min: no adjustment; GFR 30-59 m L/min: 50 mg once daily; GFR < 30 m L/min: avoid use
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg once daily; Child-Pugh C: contraindicated
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Not established for patients < 18 years
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Maximum 50 mg once daily due to increased sensitivity and renal impairment risk
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
Suicidal thoughts and behaviors: Increased risk in children, adolescents, and young adults during initial treatment.
None.
Serotonin syndrome with concomitant serotonergic drugs; risk of bleeding with NSAIDs/anticoagulants; activation of mania/hypomania; bone fracture risk in elderly; hyponatremia; QT prolongation at high doses.
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Hypersensitivity to serpalan; concurrent use of MAOIs or linezolid; concurrent use of pimozide; use of MAOIs within 14 days.
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
Avoid concurrent use of alcohol; may worsen central nervous system effects. No specific food restrictions; take with or without food. Grapefruit juice has no significant interaction.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
First trimester: increased risk of structural anomalies including cardiac defects (FDA category C; animal studies show teratogenicity at clinically relevant doses). Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and preterm birth. Late third trimester: neonatal withdrawal syndrome and respiratory depression.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
Excreted into breast milk (M/P ratio 0.9). Not recommended during breastfeeding due to potential adverse effects on infant including sedation, poor feeding, and withdrawal. Consider alternative therapy.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
Due to increased plasma volume and hepatic metabolism, dose may need to be increased by 20-30% in the second and third trimesters. Monitor trough levels and adjust to maintain therapeutic range. Postpartum, decrease dose to prepregnancy levels within 48 hours.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
SERPALAN is a selective serotonin reuptake inhibitor (SSRI) used for major depressive disorder. Monitor for serotonin syndrome, especially when co-prescribed with other serotonergic drugs. Initiate at 20 mg daily; titrate to 40 mg after 4 weeks if needed. Do not abruptly discontinue; taper gradually to avoid withdrawal symptoms. Use with caution in patients with hepatic impairment (dose reduction recommended). Avoid MAOIs within 14 days.
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
Take this medication at the same time each day, with or without food.,Do not stop taking this medication suddenly; consult your doctor for a tapering schedule.,It may take 2–4 weeks to feel the full benefit; continue taking even if you do not notice immediate improvement.,Notify your doctor if you experience new or worsening anxiety, agitation, or suicidal thoughts.,Avoid alcohol while taking this medication.,Do not take other medications, including over-the-counter drugs, without consulting your doctor.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPALAN vs ALDOCLOR-150, answered by our medical review team.
SERPALAN is a Antihypertensive that works by Selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin at the presynaptic terminal.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPALAN and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPALAN is: 100 mg orally twice daily. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPALAN and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPALAN is classified as Category C. First trimester: increased risk of structural anomalies including cardiac defects (FDA category C; animal studies show teratogenicity at clinically relevant doses). Second and thir. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.